Burning Rock Biotech

company

About

Burning Rock Biotech focuses on providing individualized cancer treatment guidance for the patients.

  • 501 - 1000

Details

Last Funding Type
Series C
Last Funding Money Raised
¥850M
Industries
Biotechnology,Health Care,Medical
Founded date
Mar 1, 2014
Number Of Employee
501 - 1000
Operating Status
Active

Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment.

Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, "Guangzhou Burning Rock Medical Examination Institute Co., Ltd." is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
¥850M
Burning Rock Biotech has raised a total of ¥850M in funding over 2 rounds. Their latest funding was raised on Feb 14, 2019 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 14, 2019 Series C ¥850M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Burning Rock Biotech is funded by 1 investors. Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Series C